MRNA Perpetual Volume on Hyperliquid Topped $104 Million

Moderna (MRNA) shares fell 1% on Friday, following a 17% drop the prior day, as investors reacted to leaked data from a late-stage melanoma vaccine trial. The data, set for official release on Saturday, initially underwhelmed investors. Analysts' price targets vary, with Goldman Sachs at $137, Morgan Stanley at $95, and Citi at $80. The stock has rallied this year on hopes for its cancer treatment pipeline.

Moderna and Merck reported Phase 3 data showing their cancer vaccine, combined with Keytruda, reduced melanoma recurrence or death by 42% over two years. Long-term efficacy remains uncertain.

Moderna and Merck's personalized mRNA vaccine, intismeran, reduced melanoma recurrence risk by 42% in a late-stage trial. The vaccine, tailored to each patient's tumor, was tested on 1,137 Stage 3 melanoma patients alongside Merck's Keytruda immunotherapy. After two years, 82% of vaccine recipients showed no recurrence compared to 70% in the placebo group. The results will be presented at the European Society for Medical Oncology meeting.

Moderna and Merck reported final clinical trial results showing their personalized mRNA vaccine, combined with immunotherapy, reduced melanoma recurrence or death risk by over 40%. The vaccine is tailored to each patient's tumor mutations. Challenges include high costs and logistical hurdles. The companies aim to expand research to other cancers, like lung cancer.

Merck and Moderna reported that their personalized mRNA-based cancer vaccine, combined with Merck's Keytruda, reduced melanoma recurrence and cancer-related death by 42% in a Phase 3 trial. The trial involved 1,137 adults with surgically removed stage 2B to 4 melanoma, with 82% of patients living cancer-free two years after treatment. The vaccine is customized to each patient's tumor and has not yet been FDA-approved.

Moderna (MRNA) shares fell 17% after phase 3 trial data for its cancer vaccine showed a 42% reduction in melanoma recurrence or death risk when combined with Merck's Keytruda. Investors reacted negatively due to concerns over data robustness. The company's P/S ratio is 36.25, significantly above its historical median of 8.55, indicating high growth expectations despite ongoing unprofitability. Insider activity shows significant selling, while institutional ownership is near 80%.